Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Science

Pharmaceutical

Research

Chiesi Group

More Like This

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

• Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in Q3 2026

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

Azelis Delivers 11% Free Cash Flow Growth in H1 2025

Chiesi Group's new Biotech Center of Excellence brings the future of medicine to Parma

Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets